Risk of domestic economic fluctuations and a decline in private-sector R&D spending
First written in FY2021. 2 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023WorsenedAnnual report
「Sales in Japan account for approximately 95% of our group sales. In addition, approximately 70% of research spending in Japan is funded by private-sector companies, and our group performance cannot be separated from the effects of economic fluctuations in Japan.」
Disclosed that the concentration of sales in Japan was approximately 95%. The description of dependence on the domestic market was made more specific than the previous disclosure of more than 90%. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
Stated that there had been no material change concerning the risks of domestic economic fluctuations and a decline in private-sector R&D spending. - FY2023-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
Stated that there had been no material change concerning the risks of domestic economic fluctuations and a decline in private-sector R&D spending. - FY2021First statedAnnual report
「Sales in Japan account for more than 90% of our group sales. In addition, approximately 70% of research spending in Japan is funded by private-sector companies, and our group performance cannot be separated from the effects of economic fluctuations in Japan.」
Against the backdrop of concentration in domestic sales and dependence on private-sector research spending, first identified economic fluctuations and a significant decline in private-sector R&D spending as separate risks. Explained that sales to medical institutions mitigate the impact.